Navigation Links
Resverlogix is Presenting at IAS HDL Workshop
Date:10/11/2007

Novel ApoA-I/HDL raising drug, RVX-208, to be featured in oral presentation

TSX Exchange Symbol: RVX

CALGARY, Oct. 11 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that tomorrow it is making an oral presentation highlighting key scientific data of its lead clinical molecule, RVX-208, at the International Atherosclerosis Society (IAS) Workshop on HDL. The presentation titled "A novel drug that raises apolipoprotein A-I and HDL in vitro and in vivo" will be presented by Dr. Norman Wong, Resverlogix Co-Founder and Chairman of the Scientific Advisory Board on October 12th at the Petros M. Nomikos Conference Center in Santorini, Greece.

"This meeting of the IAS attracts internationally elite scientists in cardiovascular medicine. This venue is ideal for announcing the favorable and novel features of RVX-208, scheduled for clinical trials later this year," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. Dr. Johansson added, "RVX-208 is a small molecule for oral administration that has shown to have unprecedented effects in raising ApoA-I and functional HDL. There is an ever-increasing body of evidence from predictive animal models that indicates RVX-208's potential for preventing and regressing atherosclerosis. We are very happy to participate in this important conference."

Mr. Donald McCaffrey, President and CEO of Resverlogix said, "These highly regarded researchers who will be participating at the event clearly understand that there is a large unmet medical need in cardiovascular disease (CVD). There is a lot of excitement among these key opinion leaders that Resverlogix's novel small molecule drug could address many of the shortcomings of current CVD drugs."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that

reflect the current views and/or expectations of Resverlogix Corp. with

respect to its performance, business and future events. Such statements

are subject to a number of risks, uncertainties and assumptions. Actual

results and events may vary significantly. The TSX Exchange does not

accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... Scientists at two major cancer research centers say older patients who have ... are younger. Surviving Mesothelioma has just published an article on the new research. ... Universities analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database to determine ...
(Date:5/27/2016)... ... 27, 2016 , ... Weeks after hosting a carpal tunnel syndrome workshop with ... surgeon and founder of the Fitzmaurice Hand Institute, has announced the addition of MRI ... state-of-the-art technology and only 1 of about 3 currently available in the United States. ...
(Date:5/26/2016)... May 26, 2016  Agriculture nutrients are in the ... Iowa is running their nitrate removal system ... Erie and coastal regions nationwide are painting ... this widespread issue. NECi Superior Enzymes, a ... Peninsula, developed a new, easy to use device that ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... and manufacturing company, today announced several positive developments that position the Company for ... a result of the transaction, Craig F. Kinghorn has been appointed Chairman of ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):